Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology - Test2 - elhamkhani - TriplyDB

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

http://www.wikidata.org/entity/Q24805922

about

Examining the Role of Vasopressin in the Modulation of Parental and Sexual Behaviors Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design Hemorrhagic shock: The "physiology approach"Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors The influence of heart failure self-care on health outcomes: hypothetical cardioprotective mechanisms.Clinical response to arginine vasopressin therapy after paediatric cardiac surgery.The incidence of vasoplegia in adult patients with right-sided congenital heart defects undergoing cardiac surgery and the correlation with serum vasopressin concentrations Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.Renal function interferes with copeptin in prediction of major adverse cardiac events in patients undergoing vascular surgery.Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters Serum vasopressin response in patients with intradialytic hypotension: a pilot study.Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice Plasma copeptin levels are inversely associated with intima-media-thickness in men: the population-based KORA F4 study.Vasopressin in the pediatric cardiac intensive care unit: Myth or reality.Established and novel biomarkers in ST-elevation myocardial infarction.Mechanisms in the bed nucleus of the stria terminalis involved in control of autonomic and neuroendocrine functions: a review.Limitations and vulnerabilities of the neonatal cardiovascular system: considerations for anesthetic management.Vasogenic shock physiology.Modern resuscitation of hemorrhagic shock: what is on the horizon?VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist.Experimental cardiac arrest treatment with adrenaline, vasopressin, or placebo.Increased vasopressin transmission from the paraventricular nucleus to the rostral medulla augments cardiorespiratory outflow in chronic intermittent hypoxia-conditioned rats.Outcomes of correcting hyponatremia in patients with myocardial infarction.Hypothalamic-Pituitary-Adrenal Axis Modulation of Glucocorticoids in the Cardiovascular System.Revisiting vasopressin and heart failure.Selective V1a receptor agonist FE 202158 reverses platelet-activating factor-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats.Supplemental arginine vasopressin during the resuscitation of severe hemorrhagic shock preserves renal mitochondrial function.Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species.Regulation of plasma vasopressin and renin activity in conscious hindlimb-unloaded rats.Nitric oxide in enteric nervous system mediated the inhibitory effect of vasopressin on the contraction of circular muscle strips from colon in male rats.A common humoral background of intraocular and arterial blood pressure dysregulation.Epigenetic Programming of Synthesis, Release, and/or Receptor Expression of Common Mediators Participating in the Risk/Resilience for Comorbid Stress-Related Disorders and Coronary Artery Disease.Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study

P2860

Q26781514-6D58CC3E-DC54-44B9-A2F6-5E2A2AEF5EDD Q27680631-736339A5-EF10-4817-A973-95541762B296 Q30424906-A7CFD911-07BF-4819-9517-E7A4FC69CAC7 Q33650270-C95169F3-8A68-47B7-9412-B50558CE4DBE Q33897455-9B02BBF2-2BF3-488A-B64E-122D4F4191B8 Q34288716-FD213FD0-CB7C-42C2-9EC3-902F55F1B069 Q34587628-9D81D4BF-FFCA-4CD3-86C6-1DF60A11C8A3 Q34601701-DCB2E409-AFB8-446A-B02E-484001234CF2 Q35392693-B415BA81-CEFA-47CF-AADB-22B1992BCC46 Q35739686-D2366EBB-C377-4A80-907A-D3A08E8786DD Q36662018-8ED2597A-43EF-4121-BB09-74224597F70A Q37279918-92FC315E-83F9-4F63-9907-07550A1BA9F3 Q37306950-28F081E0-E9B2-4405-8626-D59F88615C06 Q37714346-36E9BE80-BAA8-47A5-AE38-3BB3C17D6592 Q37907327-5F7D768B-7BDC-417B-B543-819719194BFE Q38133552-6BD98181-6F10-44AE-B723-CD428ED84C02 Q38170570-F732F623-4ABD-4E7E-8A89-8678E00DE9EA Q38448330-70DA7631-6A00-41E1-ABCF-CBDCEF47A60B Q38712960-ED4BE5BE-9F9B-4578-9803-70D058477A25 Q39819177-AFB77BB8-AFA6-4829-8DE9-5EC99916F13C Q42743367-525AE3C3-1124-45D6-9C68-E6DF158A5936 Q43201829-C2419AD0-58BB-472F-8480-FAB693600629 Q44335751-92B2DD9D-AE3B-4045-BF04-DB1B75FF9159 Q45351708-EE1F9437-ADA3-4DD9-B927-0298B7782C2C Q45352471-72AF3DC4-0D6C-4494-87AA-11E7276115CF Q45767561-7DE63C07-8614-4B64-ACF5-17D03E89EDDC Q46099570-EFEBC7B6-6393-4DCD-97FE-0F67DAA759C0 Q46247412-5386EF4E-054D-473C-8FDE-0AAC1A8479E1 Q46937426-3ABEE520-9FBC-48FD-871E-D37EA0416FDB Q48304080-79F92BFC-4CFC-4CC0-9B12-251F8DB9133F Q50010662-C944B2FE-752E-4DEA-B31D-7296F7A4E90F Q55279696-526712E3-1BF5-4DC5-84C9-F35710EEC4EC Q57052265-61B6C0C1-CF09-4B08-831A-52C100C48580

P2860

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

http://www.wikidata.org/entity/Q24805922

description

2004 nî lūn-bûn

@nan

2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@ast

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@en

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@nl

type

label

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@ast

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@en

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@nl

prefLabel

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@ast

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@en

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@nl

P1433

Q24805922-64168665-0077-4C03-9168-C7E97F99EEE3

P1476

Q24805922-F671AF56-B7CF-4045-8FD6-635D5CAB50EC

P2093

Q24805922-0EDCBC0D-7B8F-4B88-87B8-B974128E4BE1

Q24805922-6350E210-3291-4BAE-A416-F82C1D1A1FF5

Q24805922-66EFB671-AA55-47C0-BBA8-A695B192589E

P2860

Q24805922-00055BDE-7945-4F09-950A-06A0912575EF

Q24805922-09E516B5-3AF4-4118-85AD-7508529B12B7

Q24805922-0AFE8F71-C601-4F3A-8B99-22FEC8F8EB79

Q24805922-0DBEF37C-2128-4007-8685-899B7DD30078

Q24805922-10D663B7-63EE-4B8B-84E4-D89D19E2E530

Q24805922-17076C60-61B9-4B4F-8919-69E18CA71608

Q24805922-1C08B83F-19E0-4657-82A5-036BF3E8CFD2

Q24805922-1D26C8D7-89B9-43D5-BDD8-EDC510F3D839

Q24805922-22FF35F0-2434-4296-9FFF-6E5506CA990E

Q24805922-24A8A36F-8D65-46B0-8FB7-37A3763F8960

P2888

Q24805922-EABED7C3-8A95-4AB5-B85D-8B3C3734F6FE

P304

Q24805922-BF031B06-A88E-4514-ADC3-D945D7A90DB4

P31

Q24805922-294E5931-8366-4091-9316-5706B6089836

Q24805922-33D79381-FC84-436E-B152-1F985789FEDE

P356

Q24805922-44929FA6-2E63-4D42-83F5-E138BBCF1AAE

P407

Q24805922-4DA772EF-E5F9-422B-A687-7C1F860D7E6D

P433

Q24805922-1F54A220-A511-4A4F-8E6B-447296C5B70A

P478

Q24805922-CB462221-F0BB-4DD4-B554-5C7E79E182D9

P577

Q24805922-A549BF57-F470-49B6-9C19-E3CDD3B14FC1

Q24805922-CFC58B61-3A33-4A28-A36C-EF55E18B40D1

P5875

Q24805922-3D185821-1C9A-46A9-9332-DE2EC47EF7CA

P698

Q24805922-89BCE679-BF73-41EC-A36F-758C7C256F47

P921

Q24805922-038B71B4-4024-4BCC-B423-D64FCFCB239A

Q24805922-0F7CD0B2-C45D-44F1-9AB7-1572903B9B85

Q24805922-3DE02A5C-7165-4423-BCDE-E8F2E369B994

Q24805922-4F5F89B4-D76D-4BC0-A4D0-E67AAFBC8B42

Q24805922-5403F496-DD20-4EF2-B702-151A57844A48

Q24805922-67EAC6B7-EC8C-4E8E-9716-AC954170A06D

Q24805922-6ed9fa13-77eb-47d1-a3b1-4cec7acfd243

Q24805922-95E786E7-FD32-4920-BD3E-EE5D2FB1BC03

Q24805922-CF10C4A2-8FC6-4932-A2A9-6267C92C48E4

Q24805922-E1056473-01AA-460A-82B4-7F60D5DF6E3E

P932

Q24805922-89255959-231C-4138-8081-C02E15624E69

P356

P1433

P1476

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology

@en

P2093

Cheryl L Holmes

http://www.w3.org/2001/XMLSchema#string

Donald W Landry

http://www.w3.org/2001/XMLSchema#string

John T Granton

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha

The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog

Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension

Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure

ANG II and vasopressin stimulate calcium entry in dispersed smooth muscle cells of preglomerular arterioles.

Ion channels and vascular tone.

Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial.

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

Cyclic AMP selectively enhances bradykinin receptor synthesis and expression in cultured arterial smooth muscle. Inhibition of angiotensin II and vasopressin response.

Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase.

P2888

P304

15-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC2338

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8687952

http://www.w3.org/2001/XMLSchema#string

P698

14975041

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

toxic shock syndrome

nerve tissue proteins

human musculoskeletal system

P932

420051

http://www.w3.org/2001/XMLSchema#string